Nova Satra Dx uses a non-invasive blood-based diagnostic test

Singapore medtech startup Nova Satra Dx has raised US$2 million in a seed round fully subscribed by Genting Bio Cellular Sdn Bhd (a wholly-owned subsidiary of Genting Berhad.

Additionally, two directors nominated by Genting Bio have joined Nova Satra’s board.

The molecular diagnostics company will use the newly-raised capital to pay for the regulatory approval and commercialisation of its lead test, a non-invasive blood-based diagnostic test for breast cancer.

Its diagnostic tests is based on a University of Oxford developed epigenetic platform technology, using highly stable DNA-based targets as part of chromosomal signatures — which, in a nutshell, enables cancer testing to be more accurate, less painful, and less costly.

Other diagnostic tests in Nova Satra’s pipeline include colon cancer, lung cancer, prostate cancer and stomach cancer.

—

Image Credit: Nova Satra

Want to be part of the ecosystem?

Register for your Echelon Asia Summit access pass now! Enjoy +10% off Echelon Asia Summit Startup, Investor and Corporate passes just for being our favourite e27 reader:

The post Singapore medtech startup Nova Satra Dx raises US$2M to improve breast cancer testing appeared first on e27.